MY187357A - Pharmaceutical composition comprising bisoprolol and perindoril - Google Patents
Pharmaceutical composition comprising bisoprolol and perindorilInfo
- Publication number
- MY187357A MY187357A MYPI2017701538A MYPI2017701538A MY187357A MY 187357 A MY187357 A MY 187357A MY PI2017701538 A MYPI2017701538 A MY PI2017701538A MY PI2017701538 A MYPI2017701538 A MY PI2017701538A MY 187357 A MY187357 A MY 187357A
- Authority
- MY
- Malaysia
- Prior art keywords
- bisoprolol
- pharmaceutical composition
- perindoril
- composition
- perindopril
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Fixed pharmaceutical composition comprising a beta blocker, bisoprolol, and an angiotensin converting enzyme inhibitor, perindopril, and use of said composition in the treatment and prevention of cardiovascular diseases and more especially arterial hypertension, stable coronary artery disease or chronic heart failure. Medicaments.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1460654A FR3027803B1 (en) | 2014-11-05 | 2014-11-05 | PHARMACEUTICAL COMPOSITION COMPRISING A BETABLOQUANT AND A CONVERSION ENZYME INHIBITOR |
| PCT/FR2015/052975 WO2016071631A1 (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising bisoprolol and perindoril |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY187357A true MY187357A (en) | 2021-09-22 |
Family
ID=52345359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017701538A MY187357A (en) | 2014-11-05 | 2015-11-04 | Pharmaceutical composition comprising bisoprolol and perindoril |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP3215130B1 (en) |
| CY (1) | CY1123322T1 (en) |
| DK (1) | DK3215130T3 (en) |
| EA (1) | EA032808B1 (en) |
| ES (1) | ES2811904T3 (en) |
| FR (1) | FR3027803B1 (en) |
| GE (2) | GEP20196989B (en) |
| HR (1) | HRP20201518T1 (en) |
| HU (1) | HUE051947T2 (en) |
| LT (1) | LT3215130T (en) |
| MA (1) | MA40915B1 (en) |
| MX (1) | MX372717B (en) |
| MY (1) | MY187357A (en) |
| PH (1) | PH12017500786B1 (en) |
| PL (1) | PL3215130T3 (en) |
| PT (1) | PT3215130T (en) |
| RS (1) | RS60657B1 (en) |
| RU (1) | RU2702362C2 (en) |
| SG (2) | SG10201903656RA (en) |
| SI (1) | SI3215130T1 (en) |
| TN (1) | TN2017000170A1 (en) |
| UA (1) | UA122131C2 (en) |
| WO (1) | WO2016071631A1 (en) |
| ZA (1) | ZA201703078B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024004714A (en) | 2021-10-20 | 2024-05-10 | Servier Lab | Novel trimetazidine salts. |
| AR132479A1 (en) | 2023-04-20 | 2025-07-02 | Servier Lab | NEW SOLID PHASES OF TRIMETAZIDINE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501546B1 (en) | 2002-05-03 | 2012-10-10 | Hexal AG | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| WO2007010501A2 (en) * | 2005-07-22 | 2007-01-25 | Ranbaxy Laboratories Limited | A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor |
| HU230877B1 (en) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stable combination medicine |
| EP2424509A4 (en) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | Fixed dose drug combination formulations |
| EA201691986A1 (en) | 2010-05-06 | 2017-03-31 | СиЭйЭл ИНТЕРНЕШНЛ ЛИМИТЕД | PHARMACEUTICAL COMPOSITION CONTAINING ASPIRIN AND BISOPROLOL |
-
2014
- 2014-11-05 FR FR1460654A patent/FR3027803B1/en active Active
-
2015
- 2015-11-03 MA MA40915A patent/MA40915B1/en unknown
- 2015-11-04 SI SI201531387T patent/SI3215130T1/en unknown
- 2015-11-04 GE GEAP201514507A patent/GEP20196989B/en unknown
- 2015-11-04 SG SG10201903656RA patent/SG10201903656RA/en unknown
- 2015-11-04 HR HRP20201518TT patent/HRP20201518T1/en unknown
- 2015-11-04 UA UAA201705309A patent/UA122131C2/en unknown
- 2015-11-04 MY MYPI2017701538A patent/MY187357A/en unknown
- 2015-11-04 PL PL15807949T patent/PL3215130T3/en unknown
- 2015-11-04 SG SG11201703550SA patent/SG11201703550SA/en unknown
- 2015-11-04 TN TN2017000170A patent/TN2017000170A1/en unknown
- 2015-11-04 RU RU2017115341A patent/RU2702362C2/en active
- 2015-11-04 GE GEAP201914507A patent/GEAP201914507A/en unknown
- 2015-11-04 EA EA201790772A patent/EA032808B1/en unknown
- 2015-11-04 RS RS20200954A patent/RS60657B1/en unknown
- 2015-11-04 HU HUE15807949A patent/HUE051947T2/en unknown
- 2015-11-04 DK DK15807949.1T patent/DK3215130T3/en active
- 2015-11-04 PT PT158079491T patent/PT3215130T/en unknown
- 2015-11-04 WO PCT/FR2015/052975 patent/WO2016071631A1/en not_active Ceased
- 2015-11-04 EP EP15807949.1A patent/EP3215130B1/en not_active Revoked
- 2015-11-04 MX MX2017005848A patent/MX372717B/en active IP Right Grant
- 2015-11-04 ES ES15807949T patent/ES2811904T3/en active Active
- 2015-11-04 LT LTEP15807949.1T patent/LT3215130T/en unknown
-
2017
- 2017-04-27 PH PH12017500786A patent/PH12017500786B1/en unknown
- 2017-05-04 ZA ZA201703078A patent/ZA201703078B/en unknown
-
2020
- 2020-09-07 CY CY20201100839T patent/CY1123322T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE051947T2 (en) | 2021-03-29 |
| RU2702362C2 (en) | 2019-10-08 |
| TN2017000170A1 (en) | 2018-10-19 |
| RS60657B1 (en) | 2020-09-30 |
| EA032808B1 (en) | 2019-07-31 |
| EP3215130A1 (en) | 2017-09-13 |
| GEP20196989B (en) | 2019-07-10 |
| MX372717B (en) | 2020-05-26 |
| PH12017500786A1 (en) | 2017-10-02 |
| PH12017500786B1 (en) | 2023-10-11 |
| FR3027803A1 (en) | 2016-05-06 |
| CY1123322T1 (en) | 2021-12-31 |
| RU2017115341A3 (en) | 2019-05-21 |
| MX2017005848A (en) | 2017-06-27 |
| HRP20201518T1 (en) | 2020-12-11 |
| UA122131C2 (en) | 2020-09-25 |
| EP3215130B1 (en) | 2020-07-08 |
| EA201790772A1 (en) | 2017-09-29 |
| SI3215130T1 (en) | 2020-11-30 |
| FR3027803B1 (en) | 2018-02-09 |
| RU2017115341A (en) | 2018-11-05 |
| GEAP201914507A (en) | 2019-03-11 |
| SG11201703550SA (en) | 2017-06-29 |
| ES2811904T3 (en) | 2021-03-15 |
| WO2016071631A1 (en) | 2016-05-12 |
| PT3215130T (en) | 2020-08-26 |
| PL3215130T3 (en) | 2020-11-16 |
| MA40915B1 (en) | 2020-08-31 |
| ZA201703078B (en) | 2020-11-25 |
| SG10201903656RA (en) | 2019-05-30 |
| LT3215130T (en) | 2020-08-25 |
| DK3215130T3 (en) | 2020-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| EP4570314A3 (en) | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure | |
| MX2020009780A (en) | Autotaxin inhibitor compounds. | |
| MA34019B1 (en) | ARYLTRIAZOLONE RELATED TO A BIS-ARYL AND USE THEREOF | |
| EA201500934A1 (en) | CARDIO AND NEPHROPROTECTIVE ANTI-DIABETIC THERAPY | |
| EP3808367A3 (en) | Targeting aneurysm disease by modulating phagocytosis pathways | |
| EP3261671A4 (en) | Combination therapy for treatment of coronary artery disease | |
| MX2018002546A (en) | COMPOSITIONS THAT INCLUDE A UROLITINE COMPOUND. | |
| WO2015179823A3 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
| PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
| UA118474C2 (en) | (S) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE | |
| MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
| MY187357A (en) | Pharmaceutical composition comprising bisoprolol and perindoril | |
| GB2549031A (en) | Methods and drug therapies for patency of occluded blood vessels following angioplasty | |
| PH12017501979A1 (en) | Pharmaceutical compound | |
| MD4763B1 (en) | Pharmaceutical composition | |
| WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
| WO2016144704A3 (en) | Heterocyclic autotaxin inhibitor compounds | |
| PH12020500295A1 (en) | Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same | |
| TN2018000344A1 (en) | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid | |
| LT3609486T (en) | SARPOGRELATE FOR USE IN THE TREATMENT OF HEART DISEASES IN MAMMALS | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| HK40044342A (en) | New pharmaceutical use for the treatment of heart failure | |
| TH1501007280A (en) | Oral formulation for the treatment of heart and circulatory diseases. (Cardiovascular Diseases) |